{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:24:14Z","timestamp":1783031054984,"version":"3.54.6"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015439","name":"Centres de Recerca de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015439","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023553","name":"Spanish Association for Cancer Research","doi-asserted-by":"publisher","award":["PRYGN234975MENE"],"award-info":[{"award-number":["PRYGN234975MENE"]}],"id":[{"id":"10.13039\/501100023553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","award":["CPP2021-008676"],"award-info":[{"award-number":["CPP2021-008676"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","award":["CPP2022-009759"],"award-info":[{"award-number":["CPP2022-009759"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","award":["PID2022-142966OB-I00"],"award-info":[{"award-number":["PID2022-142966OB-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007320","name":"Albert Einstein Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["ERC-PoC-957466 IT4B-T-ALL"],"award-info":[{"award-number":["ERC-PoC-957466 IT4B-T-ALL"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["ERC-PoC-101100665 BiTE-CAR"],"award-info":[{"award-number":["ERC-PoC-101100665 BiTE-CAR"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CPP2021-008676"],"award-info":[{"award-number":["CPP2021-008676"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CPP2022-009759"],"award-info":[{"award-number":["CPP2022-009759"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["MICIU\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["MICIU\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.exphem.2026.105424","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:14:52Z","timestamp":1774311292000},"page":"105424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A roadmap for systematic humanization of a chimeric antigen receptor: preclinical validation of a humanized CD22 scFv as a model"],"prefix":"10.1016","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-1080","authenticated-orcid":false,"given":"Narc\u00eds","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Petazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Mulens-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Garc\u00eda","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8224-4468","authenticated-orcid":false,"given":"Pablo","family":"Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-7576","authenticated-orcid":false,"given":"V\u00edctor M.","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2026.105424_bib0001","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.exphem.2026.105424_bib0002","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10555-025-10261-7","article-title":"CAR T-cells for acute leukemias in children: current status, challenges, and future directions","volume":"44","author":"Dourthe","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.exphem.2026.105424_bib0003","first-page":"90","article-title":"Clinical pharmacology of CAR-T cells: linking cellular pharmacodynamics to pharmacokinetics and antitumor effects","volume":"1865","author":"Norelli","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.exphem.2026.105424_bib0004","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.exphem.2026.105424_bib0005","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1189\/jlb.5RU0817-315R","article-title":"Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy","volume":"102","author":"Wang","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.exphem.2026.105424_bib0006","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2026.105424_bib0007","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1042\/BST20160037","article-title":"Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview","volume":"44","author":"Lamers","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.exphem.2026.105424_bib0008","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.exphem.2026.105424_bib0009","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2026.105424_bib0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/ajh.26506","article-title":"Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed\/refractory acute lymphoblastic leukemia","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2026.105424_bib0011","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1158\/1078-0432.CCR-19-0916","article-title":"Treatment with humanized selective CD19CAR-T cells shows efficacy in highly treated B-ALL patients who have relapsed after receiving murine-based CD19CAR-T therapies","volume":"25","author":"Zhao","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2026.105424_bib0012","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105424_bib0013","article-title":"Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma","volume":"11","author":"Negishi","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.exphem.2026.105424_bib0014","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","article-title":"Acute lymphocytic leukaemia","volume":"406","author":"Kantarjian","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2026.105424_bib0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood.2021014840","article-title":"CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies","volume":"140","author":"Bueno","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105424_bib0016","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2026.105424_bib0017","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-020-00878-2","article-title":"Correction to: bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2026.105424_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011549","article-title":"CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy","volume":"13","author":"Myers","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.exphem.2026.105424_bib0019","doi-asserted-by":"crossref","first-page":"e000896","DOI":"10.1136\/jitc-2020-000896","article-title":"Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope","volume":"8","author":"Velasco-Hernandez","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.exphem.2026.105424_bib0020","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2021.08.033","article-title":"A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL","volume":"30","author":"Zanetti","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2026.105424_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009048","article-title":"CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression","volume":"13","author":"Arroyo-Rodenas","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.exphem.2026.105424_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1399438","article-title":"Prospects for the computational humanization of antibodies and nanobodies","volume":"15","author":"Gordon","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105424_bib0023","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"Rossotti","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.exphem.2026.105424_bib0024","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s43556-022-00100-4","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"3","author":"Wang","year":"2022","journal-title":"Mol Biomed"},{"key":"10.1016\/j.exphem.2026.105424_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-4939-8648-4_3","article-title":"Use of IMGT(R) databases and tools for antibody engineering and humanization","volume":"1827","author":"Lefranc","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2026.105424_bib0026","doi-asserted-by":"crossref","first-page":"W363","DOI":"10.1093\/nar\/gkm341","article-title":"M4T: a comparative protein structure modeling server","volume":"35","author":"Fernandez-Fuentes","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2026.105424_bib0027","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1074\/jbc.M706190200","article-title":"Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528","volume":"283","author":"Makabe","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2026.105424_bib0028","doi-asserted-by":"crossref","first-page":"D315","DOI":"10.1093\/nar\/gkt1189","article-title":"ArchDB 2014: structural classification of loops in proteins","volume":"42","author":"Bonet","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.exphem.2026.105424_bib0029","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/bioinformatics\/btu129","article-title":"Frag'r'Us: knowledge-based sampling of protein backbone conformations for de novo structure-based protein design","volume":"30","author":"Bonet","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.exphem.2026.105424_bib0030","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/nar\/gkl156","article-title":"A supersecondary structure library and search algorithm for modeling loops in protein structures","volume":"34","author":"Fernandez-Fuentes","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2026.105424_bib0031","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00251-011-0579-8","article-title":"NetMHCcons: a consensus method for the major histocompatibility complex class I predictions","volume":"64","author":"Karosiene","year":"2012","journal-title":"Immunogenetics"},{"key":"10.1016\/j.exphem.2026.105424_bib0032","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4049\/jimmunol.1600582","article-title":"Pan-Specific prediction of peptide-MHC class I complex stability, a correlate of T cell immunogenicity","volume":"197","author":"Rasmussen","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2026.105424_bib0033","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/acs.jproteome.9b00874","article-title":"Improved Prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data","volume":"19","author":"Reynisson","year":"2020","journal-title":"J Proteome Res"},{"key":"10.1016\/j.exphem.2026.105424_bib0034","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1021\/acs.molpharmaceut.8b00536","article-title":"Susceptibility of antibody CDR residues to chemical modifications can be revealed prior to antibody humanization and aid in the lead selection process","volume":"15","author":"Xu","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.exphem.2026.105424_bib0035","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.exphem.2026.105424_bib0036","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/978-1-4939-8736-8_21","article-title":"High-throughput antibody structure modeling and design using ABodyBuilder","volume":"1851","author":"Leem","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2026.105424_bib0037","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1080\/19420862.2016.1205773","article-title":"ABodyBuilder: automated antibody structure prediction with data-driven accuracy estimation","volume":"8","author":"Leem","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.exphem.2026.105424_bib0038","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/protein\/3.5.433","article-title":"Sequence differences between glycosylated and non-glycosylated Asn-X-Thr\/Ser acceptor sites: implications for protein engineering","volume":"3","author":"Gavel","year":"1990","journal-title":"Protein Eng."},{"key":"10.1016\/j.exphem.2026.105424_bib0039","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/jps.21868","article-title":"Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation","volume":"99","author":"Brych","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.exphem.2026.105424_bib0040","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/jps.24430","article-title":"Developability assessment during the selection of novel therapeutic antibodies","volume":"104","author":"Jarasch","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.exphem.2026.105424_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100736","article-title":"Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions","volume":"9","author":"Sydow","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2026.105424_bib0042","doi-asserted-by":"crossref","first-page":"11211","DOI":"10.1074\/jbc.M110.185041","article-title":"N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies","volume":"286","author":"Liu","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2026.105424_bib0043","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","article-title":"RGD and other recognition sequences for integrins","volume":"12","author":"Ruoslahti","year":"1996","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.exphem.2026.105424_bib0044","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1242\/jcs.03098","article-title":"Integrin ligands at a glance","volume":"119","author":"Humphries","year":"2006","journal-title":"J Cell Sci"},{"key":"10.1016\/j.exphem.2026.105424_bib0045","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1073\/pnas.88.3.1044","article-title":"CD11c\/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen","volume":"88","author":"Loike","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2026.105424_bib0046","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4161\/mabs.3.3.15608","article-title":"Fragmentation of monoclonal antibodies","volume":"3","author":"Vlasak","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.exphem.2026.105424_bib0047","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/prot.26477","article-title":"Predicting binding affinity changes from long-distance mutations using molecular dynamics simulations and Rosetta","volume":"91","author":"Wells","year":"2023","journal-title":"Proteins"},{"key":"10.1016\/j.exphem.2026.105424_bib0048","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12859-020-03770-5","article-title":"SPServer: split-statistical potentials for the analysis of protein structures and protein-protein interactions","volume":"22","author":"Aguirre-Plans","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.exphem.2026.105424_bib0049","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1073\/pnas.1802378115","article-title":"Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors","volume":"115","author":"Aleman","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2026.105424_bib0050","doi-asserted-by":"crossref","first-page":"e1375","DOI":"10.1371\/journal.pntd.0001375","article-title":"Crystal structure of the complex mAb 17.2 and the C-terminal region of Trypanosoma cruzi P2beta protein: implications in cross-reactivity","volume":"5","author":"Pizarro","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.exphem.2026.105424_bib0051","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4161\/mabs.23977","article-title":"Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig) molecule","volume":"5","author":"Jakob","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.exphem.2026.105424_bib0052","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/19420862.2019.1624463","article-title":"Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease","volume":"11","author":"Benschop","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.exphem.2026.105424_bib0053","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/prot.22087","article-title":"Structural classification of CDR-H3 revisited: a lesson in antibody modeling","volume":"73","author":"Kuroda","year":"2008","journal-title":"Proteins"},{"key":"10.1016\/j.exphem.2026.105424_bib0054","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.AID-0012-2013","article-title":"Antibody Structure","volume":"2","author":"Stanfield","year":"2014","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.exphem.2026.105424_bib0055","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1186\/s12967-024-05362-w","article-title":"Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy","volume":"22","author":"Wang","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.exphem.2026.105424_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2026.105424_bib0057","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:13:44Z","timestamp":1783030424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X26000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"alternative-id":["S0301472X26000573"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105424","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A roadmap for systematic humanization of a chimeric antigen receptor: preclinical validation of a humanized CD22 scFv as a model","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Experimental Hematology.","name":"copyright","label":"Copyright"}],"article-number":"105424"}}